A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Inclusion Criteria: * Healthy Japanese males aged ≥20 and ≤40 years of age * Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to Hepatitis C virus Exclusion Criteria: * Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP * History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator.